Loading stock data…
MDxHealth SA (MDXH)
$0.40-0.03 (-6.28%)
Market ClosedLast close Jun 29
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MDxHealth SA in the Healthcare sector is trading at $0.40 with a market capitalization of $28M. Wall Street consensus targets $2.90 (5 analysts), implying a +625.0% move over the next 12 months. The stock is currently near its 52-week low of $0.40, remaining 86.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +625.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $27.39M↓ | $29.55M↑ | $27.43M↑ | $26.61M↑ | $24.29M |
| Gross Profit | $16.61M↓ | $18.69M↑ | $17.88M↑ | $17.57M↑ | $15.50M |
| Operating Income | -$7.30M↓ | -$6.22M↓ | -$2.64M↓ | -$1.92M↑ | -$4.59M |
| Net Income | -$8.87M↑ | -$8.93M↓ | -$8.01M↓ | -$7.37M↑ | -$9.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
164.01%
Volume
Today's trading volume
1.24M
Recent News
MDxHealth SA (MDXH) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Focus Amid ...
MDxHealth SA (MDXH) reports robust revenue growth and strategic advancements, despite facing reimbursement challenges and operational losses.
MDxHealth (MDXH) Q1 2026 Earnings Transcript
With me today is Ron Kalfus, Interim Chief Financial Officer. Over the past few years, our aggressive growth strategy and commercial execution have positioned MDxHealth as the leader in precision diagnostics focused specifically in urology.
MDxHealth Q1 Earnings Call Highlights
MDxHealth (NASDAQ:MDXH) reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas, laboratory facility, a move executives said will sharpen the company’s focus on prostate cancer diagnostic
MDxHealth Reports Q1 2026 Results: Full Earnings Call Transcript
On Wednesday, MDxHealth (NASDAQ:MDXH) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://viavid.webcasts.com/starthere.jsp?ei=1758088&tp_key=21da6e9d38 Summary MDxHealth reported Q1 2026 revenue of $27.4 million, with core prostate cance
TruBridge (TBRG) Surpasses Q1 Earnings Estimates
TruBridge (TBRG) delivered earnings and revenue surprises of +15.69% and -3.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?